[Retracted] A Systematic Review and Meta-Analysis of Therapeutic Efficacy and Safety of Alirocumab and Evolocumab on Familial Hypercholesterolemia

Table 2

Prespecified safety end points. No statistical differences between the PCSK9-mAbs and control groups.

Pre-specified Safety endpoints	PCSK9-mAbs		Control			value
	No. of patients/objects	Rate (%)	No. of patients/objects	Rate (%)
Any adverse events	209/342	0.6111111	119/203	0.5862069	0.33	0.314
Serious adverse events	13/256	0.0507813	4/126	0.031746	0.72	0.287
Nervous system disorders	13/162	0.0802469	3/87	0.0344828	1.972	0.127
Injection site reactions	26/398	0.0653266	8/203	0.0394089	1.692	0.131
Leading to treatment discontinuation	10/257	0.0446429	4/128	0.03125	0.143	0.477
Nasopharyngitis	31/310	0.1	10/153	0.0653595	1.523	0.144
Back pain	7/151	0.0463576	2/75	0.0266667	0.508	0.377
Headache	13/277	0.0469314	7/137·	0.0510949	0.035	0.513
ALT, AST, or both	8/216	0.037037	2/107	0.0186916	0.803	0.3
Positively adjudicated cardiovascular events	14/239	0.0585774	7/125	0.056	0.01	0.563
Creatinine	10/248	0.0403226	2/128	0.0169492	1.667	0.164